These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 24120528)

  • 1. Subunit-specific mass spectrometry method identifies haptoglobin subunit alpha as a diagnostic marker in non-small cell lung cancer.
    Park J; Yang JS; Jung G; Woo HI; Park HD; Kim JW; Huh W; Ko JW; Kim H; Cho JY; Lee SY
    J Proteomics; 2013 Dec; 94():302-10. PubMed ID: 24120528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of haptoglobin peptide as a novel serum biomarker for lung squamous cell carcinoma by serum proteome and peptidome profiling.
    Okano T; Seike M; Kuribayashi H; Soeno C; Ishii T; Kida K; Gemma A
    Int J Oncol; 2016 Mar; 48(3):945-52. PubMed ID: 26783151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The diagnostic and prognostic value of ProGRP in lung cancer.
    Nisman B; Biran H; Ramu N; Heching N; Barak V; Peretz T
    Anticancer Res; 2009 Nov; 29(11):4827-32. PubMed ID: 20032442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical utility of haptoglobin in combination with CEA, NSE and CYFRA21-1 for diagnosis of lung cancer.
    Wang B; He YJ; Tian YX; Yang RN; Zhu YR; Qiu H
    Asian Pac J Cancer Prev; 2014; 15(22):9611-4. PubMed ID: 25520076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New and old biomarkers in the differential diagnosis of lung cancer: Pro-gastrin-releasing peptide in comparison with neuron-specific enolase, carcinoembryonic antigen, and CYFRA 21-1.
    Mauro C; Passerini R; Spaggiari L; Galetta D; Radice D; Lentati P; Sandri MT
    Int J Biol Markers; 2019 Jun; 34(2):163-167. PubMed ID: 30994045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer.
    Korkmaz ET; Koksal D; Aksu F; Dikmen ZG; Icen D; Maden E; Onder S; Akbiyik F; Emri S
    Clin Biochem; 2018 Aug; 58():15-19. PubMed ID: 29729229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
    Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
    Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer.
    Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS
    Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of differential diagnosis of lung cancer by use of multiple protein tumor marker combinations.
    Trulson I; Klawonn F; von Pawel J; Holdenrieder S
    Tumour Biol; 2024; 46(s1):S81-S98. PubMed ID: 38277317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New insights into the diagnostic characteristics and clinical application of serum biomarkers for lung cancer, and human epididymis protein 4 as a new biomarker?
    Li M; Zhang Y; Jiang L; Li Y; Li G; Zhou J; Yang C; Li X; Qu W; Chen Y; Chen Q; Wang S; Xing J; Huang H
    Neoplasma; 2022 May; 69(3):729-740. PubMed ID: 35471981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role.
    Wieskopf B; Demangeat C; Purohit A; Stenger R; Gries P; Kreisman H; Quoix E
    Chest; 1995 Jul; 108(1):163-9. PubMed ID: 7541742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer.
    Hoagland LF; Campa MJ; Gottlin EB; Herndon JE; Patz EF
    Cancer; 2007 Nov; 110(10):2260-8. PubMed ID: 17918261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology.
    Molina R; Augé JM; Bosch X; Escudero JM; Viñolas N; Marrades R; Ramírez J; Carcereny E; Filella X
    Tumour Biol; 2009; 30(3):121-9. PubMed ID: 19506400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-Sectional Study to Establish the Utility of Serum Tumor Markers in the Diagnosis of Lung Cancer.
    Mehta A; Parkash A; Bhatia M
    Asian Pac J Cancer Prev; 2021 Aug; 22(8):2569-2576. PubMed ID: 34452572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The diagnostic significance of single or combination lung cancer-related serum biomarkers in high risk lung cancer patients].
    Ni J; Guo Z; Zhang L
    Zhonghua Nei Ke Za Zhi; 2016 Jan; 55(1):25-30. PubMed ID: 26796649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
    Stieber P; Dienemann H; Schalhorn A; Schmitt UM; Reinmiedl J; Hofmann K; Yamaguchi K
    Anticancer Res; 1999; 19(4A):2673-8. PubMed ID: 10470218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High serum haptoglobin level is associated with tumor progression and predicts poor prognosis in non-small cell lung cancer.
    Lu J; Wang Y; Yan M; Feng P; Yuan L; Cai Y; Xia X; Liu M; Luo J; Li L
    Oncotarget; 2016 Jul; 7(27):41758-41766. PubMed ID: 27248178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum Cripto-1 is a novel biomarker for non-small cell lung cancer diagnosis and prognosis.
    Xu CH; Wang Y; Qian LH; Yu LK; Zhang XW; Wang QB
    Clin Respir J; 2017 Nov; 11(6):765-771. PubMed ID: 26605871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer.
    Pujol JL; Grenier J; Daurès JP; Daver A; Pujol H; Michel FB
    Cancer Res; 1993 Jan; 53(1):61-6. PubMed ID: 7677981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Establishment of cut-off value of serum pro-gastrin-releasing peptide for diagnosis of small cell lung cancer and evaluation on the clinical diagnosis efficiency].
    Shen D; Han BB; Chen F; Wei BJ; Cui CJ; Wang GJ; Cui W
    Zhonghua Yi Xue Za Zhi; 2017 Sep; 97(34):2657-2662. PubMed ID: 28910952
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.